Propionic acid and butyric acid inhibit lipolysis and de novo lipogenesis and increase insulin-stimulated glucose uptake in primary rat adipocytes

Emilia Heimann¹,*, Margareta Nyman², and Eva Degerman¹

¹Department of Experimental Medical Science; Lund University; Lund, Sweden; ²Department of Applied Nutrition and Food Chemistry; Lund University; Lund, Sweden

Keywords: adipocyte, metabolism, obesity, short-chain fatty acid, type 2 diabetes

Abbreviations: AMPK, AMP-activated protein kinase; ACC, acetyl-CoA carboxylase; ADA, adenosine deaminase; BA, butyric acid; BSA, bovine serum albumin; FFAR, free fatty acid receptor; GLUT, glucose transporter; GPCR, G-protein-coupled receptor; HSL, hormone-sensitive lipase; ISO, isoproterenol; KRBH, Krebs-Ringer bicarbonate-HEPES; KRH, Krebs Ringer-HEPES; PA, propionic acid; PDE, cyclic nucleotide phosphodiesterase; SCFAs, short-chain fatty acids; T2D, type 2 diabetes

Fermentation of dietary fibers by colonic microbiota generates short-chain fatty acids (SCFAs), e.g., propionic acid and butyric acid, which have been described to have “anti-obesity properties” by ameliorating fasting glycaemia, body weight and insulin tolerance in animal models. In the present study, we therefore investigate if propionic acid and butyric acid have effects on lipolysis, de novo lipogenesis and glucose uptake in primary rat adipocytes. We show that both propionic acid and butyric acid inhibit isoproterenol- and adenosine deaminase-stimulated lipolysis as well as isoproterenol-stimulated lipolysis in the presence of a phosphodiesterase (PDE3) inhibitor. In addition, we show that propionic acid and butyric acid inhibit basal and insulin-stimulated de novo lipogenesis, which is associated with increased phosphorylation and thus inhibition of acetyl CoA carboxylase, a rate-limiting enzyme in fatty acid synthesis. Furthermore, we show that propionic acid and butyric acid increase insulin-stimulated glucose uptake. To conclude, our study shows that SCFAs have effects on fat storage and mobilization as well as glucose uptake in rat primary adipocytes. Thus, the SCFAs might contribute to healthier adipocytes and subsequently also to improved energy metabolism with for example less circulating free fatty acids, which is beneficial in the context of obesity and type 2 diabetes.

Introduction

Type 2 diabetes (T2D) is a heterogenous disorder, involving insulin resistance as well as impaired insulin secretion from pancreatic β-cells.¹ In individuals who are genetically predisposed, T2D commonly arises with progressive obesity, in particular visceral obesity.²,³ Despite the fact that it is not exactly known what causes the strong and consistent association between obesity and development of T2D, spillover of fatty acids from white adipose tissue with consequent deposition in non-adipocyte cells, chronic low-grade inflammation and imbalance in the circulating hormones derived from adipose tissue are believed to be contributing factors.²,⁴,⁵ Thus, adipose tissue is an important target for prevention and treatment of T2D.

Fermentation of dietary fibers consisting of non-digestible carbohydrates, such as non-starch polysaccharides and resistant starch, by colonic microbiota generates short-chain fatty acids (SCFAs).⁶,⁷ Acetic acid, butyric acid and propionic acid are the most abundant SCFAs and they are believed to be important mediators of fermented dietary fibers on metabolism.⁸ Dietary supplementation or rectal and oral administration of SCFAs to mice and rats decreases free fatty acids and glucose concentrations in blood,⁹-¹³ but for studies in human subjects given SCFAs in the diet, the results are yet inconclusive.¹⁴,¹⁵ Moreover, animal studies show that high-fat diet supplemented with propionic acid and butyric acid improve insulin sensitivity and protect against the development of obesity and insulin resistance.¹¹,¹³ In addition, obese mice treated with butyric acid decreased their fat
content, which was consistent with loss of body weight and improved insulin tolerance, suggesting a role for butyric acid in the treatment of diet-induced obesity. The effect of SCFAs are believed to be mediated via the free fatty acid receptor (Ffar) 3 and 2, also known as G-protein-coupled receptor (GPCR) 41 and 43, respectively, which are expressed in adipose tissue. For example, Kimura et al. generated an adipose-specific Ffar2 transgenic mouse model, which was lean, and when challenged by a high-fat diet, these mice were protected against development of obesity and showed improved insulin sensitivity.

Some effects by SCFAs on adipocytes have been described, e.g., inhibition of lipolysis. However, the information is scarce regarding the impact of SCFAs on several aspects of basal and hormone-regulated lipid and glucose metabolism in primary adipocytes, which is addressed in this study.

**Results**

**Short-chain fatty acids inhibit lipolysis**

The effects of propionic acid and butyric acid on basal and stimulated lipolysis were studied in primary rat adipocytes. Adenosine deaminase (ADA), isoproterenol (ISO) and the cyclic nucleotide phosphodiesterase (PDE) 3 inhibitor OPC3911 were used to increase cAMP concentrations by different mechanisms, leading to activation of cAMP-dependent protein kinase A (PKA) and activation of hormone-sensitive lipase (HSL), which together with other proteins stimulate lipolysis. The PDE3 inhibitor is also used in order to test whether SCFAs mediate anti-lipolytic effects via the same pathway as insulin, which utilizes activation of PDE3B as a key component to inhibit lipolysis. As shown in Figure 1A and C, the presence of propionic acid or butyric acid, inhibit lipolysis stimulated via activation of the stimulatory G protein (Gs) by ISO, removal of the adenosine inhibitory effect on cAMP production by ADA or inhibition of cAMP degradation by the family-selective PDE3 inhibitor. However, the SCFAs did not have an effect on basal lipolysis. A significant inhibition of ADA-stimulated lipolysis was seen at 3 mM for propionic acid whereas 10 mM of either propionic acid or butyric acid were required for a significant inhibition of ADA- and ISO-stimulated lipolysis, as seen in Figure 1B and D. In the presence of OPC3911, basal as well as ISO-stimulated lipolysis was significantly enhanced (Fig. 1E). Furthermore, OPC3911 did not prevent the anti-lipolytic effect of propionic acid and butyric acid on ISO-stimulated lipolysis (Fig. 1F).

**Short-chain fatty acids inhibit insulin-stimulated de novo lipogenesis**

The effect of propionic acid and butyric acid on de novo lipogenesis was studied in primary rat adipocytes. It is well established that insulin stimulates the synthesis of fatty acids from e.g. glucose intermediates, known as de novo lipogenesis. As shown in Figure 2, both basal and insulin-stimulated de novo lipogenesis were inhibited by propionic acid and butyric acid, significant inhibition was seen at the lowest concentration (1 mM). To identify the molecular mechanism behind the inhibiting effect of SCFA, we studied the key enzyme ACC1 in de novo lipogenesis. In Figure 3, we show that propionic acid and butyric acid increased phosphorylation of ACC1 at serine 79. This leads to an inactivation of the enzymatic activity of ACC1. Taken together, the effect of propionic acid and butyric acid on phosphorylation of ACC1 is consistent with our finding that SCFA inhibits de novo lipogenesis.

**Short-chain fatty acids increase insulin-stimulated glucose uptake**

The effect of propionic acid and butyric acid on glucose uptake was studied in primary rat adipocytes. As shown in Figure 4A and C, basal glucose uptake was significantly decreased by both propionic acid and butyric acid. However, insulin-stimulated glucose uptake was significantly increased in the presence of propionic acid (Fig. 4A and B) due to decreased and increased glucose uptake in the absence or presence of insulin, respectively. Butyric acid did also have an effect on insulin-stimulated glucose uptake (Fig. 4C), however, the effect of butyric acid, as shown in Figure 4D, is solely due to a decreased basal glucose uptake in the presence of butyric acid (10 mM).

**Discussion**

In the literature, the beneficial effects seen with dietary fiber intake have partly been ascribed to the SCFAs. For example, results from in vivo studies in mice suggest that dietary supplementation of propionic acid and butyric acid protects against high fat diet-induced obesity by e.g., inhibiting food intake, improving insulin sensitivity and increasing energy expenditure. However, less is known regarding the role of specific cellular targets and mechanisms in mediating the overall beneficial effects on metabolism. Because adipocytes are key target cells concerning the prevention and treatment of T2D, in this study we evaluate the effects of a number of biological functions and mechanisms on primary rat adipocytes of relevance for glucose and lipid metabolism.

In adipose tissue, the hydrolysis of triacylglycerols into free fatty acids and glycerol, a process known as lipolysis, is often dysregulated in obesity, leading to excessive release of fatty acids to the plasma and decreased insulin sensitivity. In the present study, we show that propionic acid and butyric acid inhibited lipolysis stimulated by activation of Gs via isoproterenol (ISO) and inhibition of Gi via the removal of adenosine using adenosine deaminase (ADA). Also, we show that lipolysis stimulated by suppression of the cAMP degrading enzyme PDE3 is inhibited by both SCFAs. The ability of SCFAs to inhibit lipolysis when PDE3B is suppressed indicates that SCFAs do not mediate their anti-lipolytic effects via enhanced degradation of cAMP, which is the case for insulin. Furthermore, the ability of propionic acid and butyric acid to inhibit lipolysis in rat adipocytes in this process has to our knowledge not been shown previously, which has been discussed by others. However, it has been shown that acetic acid and propionic acid inhibit basal and ISO- or ADA-potentiated lipolysis in 3T3-L1 adipocytes and primary mouse...
In adipocytes, basal glucose uptake and insulin-dependent glucose uptake are mediated by glucose transporter (GLUT)1 and GLUT4, respectively. In the present study, basal glucose uptake is decreased by both propionic acid and butyric acid in rat primary adipocytes. A decreased glucose uptake by adipocytes is favorable when the body is maintaining euglycemia in a fasting condition. Mean ± SD (n = 5–13) were used and significance levels were accepted when *P < 0.05, **P < 0.01 and ***P < 0.001.
on basal lipolysis, which might have beneficial effects on glucose homeostasis in dysregulated metabolism. Liver and muscles utilize the major proportion of glucose in a postprandial state, but even though only a minor proportion of glucose is utilized by adipose tissue, it is favorable for whole body glucose homeostasis. For example, studies in mouse models with either an increased glucokinase production or with an adipocyte-specific knockdown of GLUT4 imply the favorable effect of a proper utilization of glucose in adipocytes on glucose tolerance and insulin sensitivity on the systemic level. Interestingly, GLUT4, which mediates insulin-dependent glucose uptake, is increased at the mRNA level in response to propionic acid in omental adipose tissue from overweight individuals. Another study has shown that acetic acid inhibits insulin-potentiated glucose uptake and suppresses insulin signaling via PKB in 3T3-L1 adipocytes and primary adipocytes from mice.

In the present study, concentrations in the millimolar range were required to obtain effects on primary adipocytes. Concentrations of the SCFAs fluctuate in the circulation throughout the day, which is particularly dependent on fasted and fed state, but also reflected upon time point for meal consumption. The formation and proportion of SCFAs is also dependent on several other factors, such as amount and type of indigestible carbohydrate and its accessibility in diet, fermentation capability of the residing bacterial populations and gut transit time. Measures of circulation SCFA concentrations have been done in sudden-death victims, as well as in healthy individuals and all 3 SCFAs (acetic acid > propionic acid > butyric acid) have been estimated to be in the micromolar range concentration in the systemic circulation. The net uptake (measured as the arteriovenous difference across the tissue times the tissue plasma flow) of the SCFAs by abdominal subcutaneous adipose tissue has been estimated to be 18.2 μmol/100 mL adipose tissue (AT) for acetate and 1.53 μmol/100 mL AT for propionic acid in humans received a diet supplemented with dietary fibers or placebo. However, in vitro and in the present study, it is not unusual to obtain effects by hormones and nutrient used in supra-physiological concentrations, which is a limiting factor for

Figure 2. Short-chain fatty acids inhibit de novo lipogenesis in primary rat adipocytes. De novo lipogenesis was measured after 30 min of stimulation with or without 1 mM insulin (INS) in the presence or absence of 1, 3 and 10 mM propionic acid (PA) (A and B) or butyric acid (C and D). In A and C, the values are related to BASAL, condition without insulin and SCFA. In B and D, the values for PA and BA are related to CTRL (BASAL and INS are used as CTRL in respective group), either in a basal or an insulin-stimulated state. Mean ± SD (n = 3–6) were used and significance levels were accepted when *P < 0.05, **P < 0.01 and ***P < 0.001.

Figure 3. Short-chain fatty acids inhibit de novo lipogenesis via inhibition of ACC1. Primary rat adipocytes were stimulated with insulin (INS) in the presence or absence of 3 and 10 mM propionic acid (PA) and butyric acid (BA) for 10 min. In the CTRL primary rat adipocytes were kept in a non-stimulatory condition. Homogenates were subjected to immunoblot analysis and membranes were probed for antibodies against ACC1 and phospho-ACC1 at serine 79 (S79). Quantification was made using Image Lab Software (Bio-Rad Laboratories) and data are presented as fold of insulin. Mean ± SD (n = 5–9) were used and significance levels were accepted when *P < 0.05, **P < 0.01 and ***P < 0.001.
drawing conclusions. On the other hand, cell models are important tools for evaluating target tissues and molecular mechanism behind an obtained effect in vivo.

Thus, the present study shows a number of effects of propionic acid and butyric acid on glucose and lipid metabolism that could contribute to the beneficial effects of dietary fibers on metabolism. Interestingly, the microbiota appears to be of relevance in this context. Indeed, dietary fiber intake can promote a shift in the colonic microbiota composition, leading to a change in the production of SCFAs. In humans, the microbiota differs between lean and obese individuals but whether a specific phylum is more dominant than another has still not been unraveled. T2D patients have also an altered microbiota with a notable decrease in butyric acid-generating bacteria, e.g. Roseburia species. The advantage of having a lean phenotype of the microbiota has thus been observed in individuals with a metabolic disturbance, as infusion of lean microbiota via a gastroduodenal tube improved insulin sensitivity, which also was associated with a notable increase of butyric acid-generating bacterial species, in these individuals. Although it is known that dietary habits can have effects on colonic microbiota composition and thus generation of SCFAs, as described above, the exact physiological impact of these changes needs to be further investigated.

In summary, the obtained effects by SCFAs on glucose and lipid metabolism in primary adipocytes, described herein, might be beneficial for prevention of dysfunctional adipocytes associated with insulin resistance as seen in obese and diabetic individuals. Hence, as SCFAs are prominent targets for development of functional foods for prevention of obesity and T2D, further investigations are needed to estimate the actual concentration of SCFAs that fluctuates around visceral adipose tissue as well as to elucidate the precise underlying mechanism on adipocyte function.

**Materials and Methods**

**Animal model**

Sprague Dawley males, 36 d of age, purchased from Charles River Laboratories (Germany), were kept under standardized conditions in the animal house facilities at Lund University. The Committee of ethical animal research in Malmö and Lund has approved all experimental procedures (permission number: M245–12).

**Adipocyte isolation**

Epididymal white adipose tissue was isolated and digested in collagenase for 45 min at 37°C with agitation and then washed as previously described. The total volume of packed cells (lipo- crit) in the adipocyte suspension was determined as described by Fine et al. The adipocytes were resuspended and diluted to the final cell concentration (1–10%), depending on experimental setup.

**Lipolysis**

Lipolysis was measured as described by Dole et al. Aliquots (300 μl) of a 5% suspension of adipocytes were prepared in

---

**Figure 4.** Short-chain fatty acids potentiate insulin-stimulated glucose uptake in primary adipocytes. Glucose uptake was measured after 30 min of stimulation with or without 1 nM insulin (INS) in the presence or absence of 1, 3 and 10 mM propionic acid (PA) (A and B) or butyric acid (BA) (C and D). In A and C, the values are related to BASAL CTRL, the condition without insulin and SCFA. In B and D, the values are based upon the ratio between BASAL and INS-stimulated conditions (shown in A and C). Mean ± SD (n = 4–5) were used and significance levels were accepted when *P < 0.05, **P < 0.01 and ***P < 0.001.
Krebs Ringers HEPES (KRH) containing 25 mM HEPES (pH 7.4), 120 mM NaCl, 4.7 mM KCl, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 2.5 mM CaCl₂, 1% BSA, 2 mM glucose, and 200 mM adenosine and incubated with or without 30 nM DL-Isoprotrenol hydrochloride (ISO) (Sigma-Aldrich, St. Louis, MO, USA), 10–30 U/ml adenosine deaminase (ADA) (Roche Diagnostics, Mannheim, Germany), 10 μM OPC3911 (PDE3 inhibitor) (Osaka Inc., Japan) in the presence or absence of 3 and 10 mM propionic acid (Sigma-Aldrich) or butyric acid (Sigma-Aldrich) at 37°C for 30 min in a shaking device (150 rpm). The cell-free medium was transferred to wells and buffer containing 50 mM glucose, 0.05% hydrazinehydrate, 1 mM MgCl₂, 0.75 mg/ml ATP (Sigma-Aldrich), 0.375 mg/ml NAD (Roche, Pleasanton, CA, USA), 25 μg/ml glycerol-3-phosphate dehydrogenase (Roche) and 0.5 μg/ml glycerol kinase (Roche) was added. Lipolysis was measured at optical density of 340 nm as the release of glycerol into the cell-free medium.

**Lipogenesis**

Lipogenesis was measured as described by Moody et al. Aliquots (700 μl) of a 2% suspension of adipocytes were prepared in KRH with low glucose (containing 0.55 mM glucose and 3.5% BSA without adenosine) and 14C-labeled glycerol (Novonordisk, Bagsvaerd, Denmark) in the presence or absence of 1, 3 and 10 mM propionic acid or butyric acid in a shaking device (80 rpm) at 37°C for 30 min. Incubations were stopped by addition of toluene-based scintillation liquid (VWR Chemicals, Radnor, PA, USA), 25 μCi/ml 2,5-diphenyloxazole (PPO) (Sigma-Aldrich) and 5 mg/ml 1.4-bis-[4-methyl-5-phenyl-2-oxazolyl]benzene (POPOP) (Sigma-Aldrich) and the incorporation of 3H into cellular lipids in the non-water soluble phase was determined by scintillation counting.

**Glucose uptake**

Glucose uptake was measured as described by Foley et al. Aliquots (200 μl) of a 5% suspension of adipocytes were prepared in a glucose-free KRBH buffer containing 120 mM NaCl, 4 mM KH₂PO₄, 1 mM MgSO₄, 0.75 mM CaCl₂, 10 mM NaHCO₃, 1% BSA and 30 mM HEPES (pH 7.4). 100 μl D-[1⁴C (U)] (57.8 mCi/mmol) was added as substrate for glucose uptake. The adipocyte suspensions were incubated with or without 1 nM insulin in the presence or absence of 1, 3 and 10 mM propionic acid or butyric acid in a shaking device (100 rpm) at 37°C for 30 min. Adipocytes were separated from the medium by addition of 60 μl dinonylphthalate and then briefly centrifuged. Ultima Gold scintillation liquid (PerkinElmer, Waltham, MA, USA) and 0.5 μCi/ml 1.4-bis-[4-methyl-5-phenyl-2-oxazolyl]benzene (POPOP) (Sigma-Aldrich) and the incorporation of 3H into cellular lipids in the non-water soluble phase was determined by scintillation counting.

**SDS-PAGE and Immunoblot Analysis**

Aliquots of a 10% suspension of adipocytes were used for 10 min incubations with 1 nM insulin in the presence or absence of 1, 3 and 10 mM propionic acid or butyric acid. Cells were homogenized with a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1% NP40, 1 mM Na-orthovanadate, 50 mM NaF, 5 mM Na-pyrophosphate, 0.27 M sucrose, Nonidet P 40 (Sigma-Aldrich) and supplemented with NuPAGE sample reducing agent (Novex, Grand Island, NY, USA) and Complete Protease Inhibitor (containing inhibitors for serine-, cysteine-, and metalloproteases as well as calpains) (Roche) and centrifuged at 13,600 × g for 15 min. The total protein amount was determined according to Bradford. Samples (10–15 μg) were subjected to SDS-PAGE. Proteins were electro-transferred to Amersham Hybond-C Extra nitrocellulose membranes (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) and the membranes were stained with Ponceau S (0.1% in 5% acetic acid) and then blocked with 10% milk in a buffer consisting of 20 mM Tris-HCl, pH 7.6, 137 mM NaCl and 0.1% (v/w) Tween-20 for 60 min. Membranes with proteins were probed with antibodies for acetyl CoA carboxylase 1 (ACCI) (Cell Signaling Technology, Danvers, MA, USA) and phospho-ACCI (S79) (Cell signaling Technology) and incubated overnight at 4°C. Proteins were detected using the chemiluminescent Super Signal West Pico Luminol/Enhancer solution (Thermo Fisher Scientific, Waltham, MA, USA) and the ChemiDoc XRS+ Imager (Bio-Rad Laboratories, Hercules, CA, USA). Image Lab Software (Bio-Rad Laboratories) was used for quantification.

**Statistics**

Data are presented as mean ± SD from the indicated number of experiments. Statistically significant differences were analyzed using Student’s t-test and significance levels were accepted when *P < 0.05, **P < 0.01 and ***P < 0.001.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

Eva Ohlson is acknowledged for her excellent technical assistance.

**Funding**

The study was financially supported by the Antidiabetic Food Center (AFC), a VINNOVA VINN Excellence Center at Lund University.

**Author Contributions**

All authors contributed to the design of the study and manuscript writing. EH contributed to the conduct of the study and data collection, whereas all authors contributed with analysis as well as data interpretation.
References

1. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009, Diabetologia 2010; 53:1270-7; PMID:20631178; http://dx.doi.org/10.1007/s00125-010-1684-1

2. Capurso C, Capurso A. From excess adiposity to insulin resistance: the role of free fatty acids. Vascul Pharmacol 2012; 57:97-11; PMID:22609131; http://dx.doi.org/10.1016/j.vph.2012.03.005

3. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29:2959-71; PMID:18757919; http://dx.doi.org/10.1093/eurheartj/ehn367

4. Mintz-Harfouche B. Origins of metabolic complications in obesity: adipose tissue and free fatty acid trafficking. Curr Opin Clin Nutr Metab Care 2011; 14:53; PMID:21849896; http://dx.doi.org/10.1097/MCO.0b013e32844ad6b6

5. Henry SL, Bensley JG, Wood-Bradley RJ, Cullen-MeEwen LA, Bertram JF, Armitage JA. White adipocytes: more than just fat depots. Int J Biochem Cell Biol 2012; 44:435-40; PMID:22222895; http://dx.doi.org/10.1016/j.biocel.2012.01.011

6. Everard A, Cani PD. Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol 2013; 27:73-83; PMID:23768554; http://dx.doi.org/10.1016/j.bpcg.2013.05.007

7. Al-Ahmad SH, Peppoloni MP, Roedhof H, Vonk RJ, Venema K. Biological effects of propionic acid in humans; metabolism, potential applications and underling mechanisms. Biochim Bioact Acta 2010; 1801:1175-83; PMID:20691280; http://dx.doi.org/10.1016/j.bbagen.2010.09.007

8. den Besten G, van Eunen K, Groen AK, Venema K. Bornet FR, Slama G. Effects of dietary propionate on cholesterol and glucose metabolism in obese rats. Br J Nutr 1999; 82:155-68; PMID:10842661; http://dx.doi.org/10.1079/1352324993256588

9. Boillot J, Alamowitch C, Berger AM, Luo J, Bruzzo F, Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2010; 59:2417-30; PMID:20623219; http://dx.doi.org/10.2337/db10-0158

10. Kimoto M, Hiemori M, Tsuji H. Improvement of day and glucose tolerance status affect serum short-chain fatty acids. J Biochem (Lond) 2008; 32:1720-4; PMID:18779823; http://dx.doi.org/10.1038/jnme.2010.118

11. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2010; 59:2417-30; PMID:20623219; http://dx.doi.org/10.2337/db10-0158

12. Moundras C, Remesy C. Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in obese rats. Br J Nutr 1995; 73:287-94; PMID:8813902; http://dx.doi.org/10.1079/BJN19950026

13. Berggren N, Nyman EM, Lundquist I, Bjorkr IM. Influence of orally and rectally administered propionate on fasting serum concentration of short-chain fatty acid in rats. Acta Physiol Scand 1979; 107:243-8; PMID:31858

14. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009; 58:1569-17; PMID:19366884; http://dx.doi.org/10.23736/S0012-5415.09.06011-1

15. Yamashita H, Fujisawa K, Ito E, Idi S, Kagawa G, Nakamura N, Kimoto M, Hiemori M, Tsuji H. Improvement of obesity and glucose tolerance by carbohydrate and lipid metabolism in normal rats. Br J Nutr 1995; 73:241-51; PMID:7718534; http://dx.doi.org/10.1079/BJN1995000632

16. Lin HV, Frassetto A, Kowalk JG, Jr., Nawrocki AR, Lu MM, Kosinski JR, Hubert JA, Sato Y, Xue Z, Forrest G, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor-dependent mechanisms. PLoS One 2012; 7:e53240; PMID:22520874; http://dx.doi.org/10.1371/journal.pone.0035240

17. Wolever TM, Spadafora P, Ehsuis H. Interaction between colonic acetate and propionate in humans. Am J Clin Nutr 1991; 53:681-7; PMID:20080222

18. Todesco T, Rao AV, Bovello O, Jenkins DJ. Propionate lowers blood glucose and alters lipid metabolism in healthy subjects. Am J Clin Nutr 1991; 54:860-5; PMID:5915117

19. Al-Ahmad SH, Roedhof H, Rezaee F, Weening D, Hoek A, Vonk R, Venema K. Propionic acid affects immune status and metabolism in adipose tissue from overweight subjects. Eur J Clin Invest 2012; 42:357-64; PMID:21931915; http://dx.doi.org/10.1111/j.1365-2362.2011.02590.x

20. Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, Terasawa K, Kashihara D, Hirano K, Tani T, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 2013; 4:1829; PMID:23620720; http://dx.doi.org/10.1038/ncomms2852

21. Al-Ahmad SH, Roedhof H, Rezaee F, Weening D, Hoek A, Vonk R, Venema K. Propionic acid affects immune status and metabolism in adipose tissue from overweight subjects. Eur J Clin Invest 2012; 42:357-64; PMID:21931915; http://dx.doi.org/10.1111/j.1365-2362.2011.02590.x

22. Wolfer TM, Josse RG, Leiter LA, Chasson JL. Time of day and glucose tolerance status affect serum short-chain fatty acids. J Circ Res 2005; 96:405-11; PMID:15993258; http://dx.doi.org/10.1161/jc.0128.2000048882

23. Bach Knudsen KE, Serena A, Canibe N, Juntunen KS. New insight into butyrate metabolism. Proc Nutr Soc 2003; 62:81-6; PMID:12740062; http://dx.doi.org/10.1079/PNS2002212

24. Nichson AC, Osman EM, Knudsen KE, Holf J, Bjorkr IM. A cereal-based evening meal rich in indigestible carbohydrate increases plasma butyrate the next morning. J Nutr 2008; 138:1912-6; PMID:18081060; http://dx.doi.org/10.1093/jn/88.10.1912

25. Soldavini J, Kauinntz JD. Pathology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity. Dig Dis Sci 2013; 58:2766-6; PMID:23839399; http://dx.doi.org/10.1007/s10620-013-2230-y

26. Cumings JH, Pomare E, Branch WJ, Naylor CP, Robertson MD, Bickerton AS, Denom Al, Vidal H, Fayaz M. Insulin-sensitising effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. Am J Clin Nutr 2005; 82:559-7; PMID:16151268

27. Walker AW, Ince J, Duncan SH, Webster LM, Holton G, Ze X, Brown D, Stares MD, Scott P, Bergerat A, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J 2011; 5:220-30; PMID:20686513; http://dx.doi.org/10.1038/ismej.2010.118

28. Duncan SH, Lobley GE, Holton G, Ince J, Johnston AM, Louis P, Flint HJ. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond) 2008; 32:1720-9; PMID:18779823; http://dx.doi.org/10.1038/ijb.2007.363

29. Ley RE, Turnbaugh PJ, Klein S, Gordon JJ. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444:1022-3; PMID:17183309; http://dx.doi.org/10.1038/4441022a

30. Kim J, Li Y, Cai Z, Lin S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, et al. A metagenome-wide...
association study of gut microbiota in type 2 diabetes. Nature 2012; 490:55-60; PMID:23023125; http://dx.doi.org/10.1038/nature11450

46. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Koorte RS, Barrelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143:913-6. e7; PMID:22728514; http://dx.doi.org/10.1053/j.gastro.2012.06.031

47. Honnor RC, Dhillon GS, Londos C. cAMP-dependent protein kinase and lipolysis in rat adipocytes. I. Cell preparation, manipulation, and predictability in behavior. J Biol Chem 1985; 260:15122-9; PMID:2415513

48. Fine JB, DiGiofolano M. A simple method to predict cellular density in adipocyte metabolic incubations. Int J Obes Relat Metab Dis 1997; 21:764-8; PMID:9376688; http://dx.doi.org/10.1038/sj.ijo.0800469

49. Dole VP, Meinertz H. Microdetermination of long-chain fatty acids in plasma and tissues. J Biol Chem 1960; 235:2595-9; PMID:13817286

50. Moody AJ, Stan MA, Stan M, Gliemann J. A simple free fat cell bioassay for insulin. Horm Metab Res 1974; 6:12-6; PMID:4819286; http://dx.doi.org/10.1055/s-0028-1093895

51. Foley JE, Kashwagi A, Verso MA, Reaven G, Andrews J. Improvement in in vitro insulin action after one month of insulin therapy in obese non-insulin-dependent diabetics. Measurements of glucose transport and metabolism, insulin binding, and lipolysis in isolated adipocytes. J Clin Invest 1983; 72:1901-9; PMID:6558258; http://dx.doi.org/10.1172/JCI111153